Drug approval processes: A case study of rivaroxaban
Rivaroxaban, a Xa inhibitor, was recently approved (March 2013) in the setting of post-acute coronary syndromes (ACS) by the European Medicine Agency. This is in contrast to not being approved by the Food and Drug Agency in the United States for the same indication in 2012 and 2013. The FDA′s decisi...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Archives of Global Professionals
2013-01-01
|
| Series: | Archives of Pharmacy Practice |
| Subjects: | |
| Online Access: | http://www.archivepp.com/article.asp?issn=2045-080X;year=2013;volume=4;issue=4;spage=186;epage=189;aulast=Arif |